227 related articles for article (PubMed ID: 35398467)
1. Evaluation of the in vitro synergy of polymyxin B-based combinations against polymyxin B -resistant gram-negative bacilli.
Li Y; Guo S; Li X; Yu Y; Yan B; Tian M; Xu B; Hu H
Microb Pathog; 2022 May; 166():105517. PubMed ID: 35398467
[TBL] [Abstract][Full Text] [Related]
2.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae.
Huang YS; Yang JL; Wang JT; Sheng WH; Yang CJ; Chuang YC; Chang SC
J Infect Public Health; 2024 May; 17(5):929-937. PubMed ID: 38599013
[TBL] [Abstract][Full Text] [Related]
4. Synergy of polymyxin B, tigecycline and meropenem against carbapenem-resistant Enterobacter cloacae complex isolates.
Alves PH; Boff RT; Barth AL; Martins AF
Diagn Microbiol Infect Dis; 2019 May; 94(1):81-85. PubMed ID: 30638946
[TBL] [Abstract][Full Text] [Related]
5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
6. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
Meschiari M; Asquier-Khati A; Tiseo G; Luque-Paz D; Murri R; Boutoille D; Falcone M; Mussini C; Tattevin P;
Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353
[TBL] [Abstract][Full Text] [Related]
7. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Turk Dagi H; Kus H; Arslan U; Tuncer I
Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates.
Mataracı Kara E; Yılmaz M; Özbek Çelik B
J Glob Antimicrob Resist; 2019 Jun; 17():137-141. PubMed ID: 30576787
[TBL] [Abstract][Full Text] [Related]
9. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant
Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB
Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
[No Abstract] [Full Text] [Related]
11. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
Liang R; Wang D; Hu M; Gu Y; Wang M; Hu D; Zhu M; Wang M
J Antibiot (Tokyo); 2023 Sep; 76(9):540-547. PubMed ID: 37217796
[TBL] [Abstract][Full Text] [Related]
12. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
13. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
[TBL] [Abstract][Full Text] [Related]
14. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
15.
Rodriguez CH; Brune A; Nastro M; Vay C; Famiglietti A
J Med Microbiol; 2020 Jul; 69(7):928-931. PubMed ID: 32584214
[No Abstract] [Full Text] [Related]
16. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
17. Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility.
Ferrer-Espada R; Sánchez-Gómez S; Pitts B; Stewart PS; Martínez-de-Tejada G
Int J Antimicrob Agents; 2020 Jul; 56(1):105986. PubMed ID: 32335279
[TBL] [Abstract][Full Text] [Related]
18. Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.
Abbey T; Vialichka A; Jurkovic M; Biagi M; Wenzler E
Microbiol Spectr; 2022 Jun; 10(3):e0054222. PubMed ID: 35647655
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
20. In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing
Kuai J; Zhang Y; Lu B; Chen H; Zhang Y; Li H; Wang Y; Wang Q; Wang H; Wang X
Infect Drug Resist; 2023; 16():3171-3182. PubMed ID: 37249967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
